Search Results

You are looking at 1 - 10 of 90 items for :

  • Behavioral Sciences x
  • Refine by Access: All Content x
Clear All

 1. Summary of results Code System Frequency DBT/MDMA-AT overlap 83 Concerns for MDMA-AT for BPD (+) 15 Modification for BPD Dx 5 Regression 4 Limitations of DBT/MDMA-AT treatment alone 0 Limitations of traditional treatment modalities (not/MDMA

Open access

/Self-Validation 4 Emotional Dysregulation 6 Understanding Emotions 4 Emotional Self-Validation 7 Wise Mind 2 Support Network 5 Stigma-Lack of Access 10 De-Stigmatization 2 Lack of Access 5 Phase 2-MDMA-AT 0 MDMA Therapy Orientation 6 Therapist Role 2 Suicidality 5

Open access

Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) have been at the forefront of addressing PTSD by working to make 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy into a legal prescription

Open access

Introduction ±3,4-Methylenedioxymethamphetamine (MDMA), the active ingredient of the street drug Ecstasy, was studied initially as an adjunct psychotherapeutic tool, prior to its nationwide prohibition. It was first termed

Open access

people with various drug dependence, all which are described later. To date, 3,4,-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy research has focused primarily on post-traumatic stress disorder (PTSD). However, MDMA has never been explored as

Open access

,4,-methylenedioxymethamphetamine (MDMA)-assisted therapist training program and have served as therapists with the MAPS-sponsored trials of MDMA-assisted treatment of PTSD at NYUSoM. Currently, both authors are also part of a team conducting a qualitative interview study of

Open access

,4-methylenedioxymethamphetamine (MDMA) being used for a variety of indications ( Costandi, 2014; Passie, 2018 ). Current clinical research is exploring the safety and efficacy of psychedelics for mental health disorders, such as posttraumatic stress disorder (PTSD), mood

Open access

for psychedelic-assisted treatments currently. For example, a recent Phase III trial of MDMA-assisted treatment for post-traumatic stress disorder represents years of herculean work performed in multiple nations and reveals a promising effect size of

Open access

, which displayed positive results for MDMA assisted psychotherapy in the treatment of post-traumatic stress disorder. Also of importance, were three seminal papers displaying the use of psilocybin for the treatment of anxiety and depression in patients

Open access

far, not the only means. The psychostimulant 3,4-Methylenedioxymethamphetamine (MDMA) is a prototypical entactogen characterized by its ability to induce acute feelings of sociability ( Regan, Margolis, de Wit, & Lyubomirsky, 2021 ) and heightened

Open access